Precision BioSciences (DTIL) Jumps on First Evidence of cccDNA Elimination in Hepatitis B

Precision BioSciences (DTIL) shares surged on May 27, 2026 after the company presented the first clinical evidence that its gene-editing therapy can eliminate covalently closed circular DNA (cccDNA) in chronic hepatitis B patients. The early-stage data, disclosed at a medical conference, showed a reduction in cccDNA levels and declines in hepatitis B surface antigen in a small Phase 1 trial cohort, with no significant safety concerns reported. Analysts said the results validate the company’s ARCUS platform and could position it as a contender for a functional cure. DTIL stock jumped more than 40% in premarket trading, reflecting investor optimism over the potential to address the viral reservoir responsible for persistent infection.